Currently Viewing:
Newsroom

Taiho's RECOURSE Trial Meets Primary Endpoint for mCRC in Phase 3

Taiho Pharmaceutical Co., parent company of Taiho Oncology, announced recently that its combination drug for refractory metastatic colorectal cancer met its primary endpoint in a phase 3 global RECOURSE trial.

The RECOURSE trial of the combined oral drugs trifluridine and tipiracil hydrochloride (TAS-102) is a global, randomized, double blind, placebo-controlled study of 800 people with refractory mCRC. Each participant had received at least two prior failed treatment attempts using standard chemotherapy and received either TAS-102 or placebo to establish the efficacy and toleration of the drug combination and improve overall survival.

“We are very pleased by the results from the phase 3 RECOURSE trial in refractory mCRC, which support TAS-102 as a potential new treatment option for this patient population,” Fabio M. Benedetti, MD, senior vice president and chief medical officer at Taiho Oncology, said in a press release.

Report: http://bit.ly/1hK7lQD

Source: Healio


 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up